Realizing the potential of adenosine-receptor-based therapeutics.
Discovery Therapeutics, Inc., Richmond, Virginia, 23230-3311, USA.
R J
RJ
Barrett
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D009636:Norbornanes / Q000494:pharmacology / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D018047:Receptors, Purinergic P1 / Q000502:physiology; D051437:Renal Insufficiency / Q000188:drug therapy; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D009636:Norbornanes; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D011720:Pyrazoles; D011725:Pyridines; D018047:Receptors, Purinergic P1; C077100:FK 453; C073387:N 0861; D013806:Theophylline; D000225:Adenine; C006683:bamifylline